Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
暂无分享,去创建一个
M. Ogura | K. Tobinai | D. Maruyama | T. Uchida | N. Uike | K. Ishizawa | T. Aoki | Takashi Watanabe | T. Takubo | K. Hatake | Tatsuya Suzuki | M. Yokoyama | T. Matsushima | Hideaki Kagehara